News About: Pharm. Industry
Rebates judge pharmaceutical companies’ destiny
The rebate investigation on pharmaceutical companies has been strongly conducted, enough to share their destiny.
While the pharmaceutical industry has internally said the prosecution-inspected company P will get dama...
Brexit alerts pharmaceutical industry, too
It seems the Brexit crisis will bring huge impacts on the domestic pharmaceutical industry, too. It rarely influences on the real economy, such as the domestic pharmaceutical economy and pharmaceutical exports, but is...
Domestic pharmaceutical companies focus on development of salt-modified drugs and generics of ‘Viread’The hepatitis B therapy which recorded KRW 125.3 billion prescriptions in Korea last year, Viread(generic name: tenofovir, Gilead), will be expired in patent. Thus, pharmaceutic...
|
AstraZeneca confirms Early Retirement Program, paying No. of year * 2 + 8-month wageAstraZeneca Korea has actively started to reduce the number of employees.
The company confirmed to run the Early Retirement Program(ERP) recently, informed it internally.
The ...
|
Hanmi strengthens sales & marketing in ophthalmologic fieldHanmi Pharm will drastically strengthen sales, marketing and R&D on the ophthalmologic field.
On the 23rd, Hanmi Pharm(CEO Kwan-soon Lee) announced reorganization of the ophth...
|
Two-faced foreign companies, tightening CP while squeezing sales
As a chain of rebate issues have hit the industry, multinational pharmaceutical companies were criticized to excessively behave on managing their partner companies.
They are known to send out official documents to i...
Will global pharmaceutical companies evacuate from Indonesia?
Many global pharmaceutical companies were recently known to evacuate their factories from Indonesia. The main cause of the phenomenon was interpreted as the lowered economic growth of Indonesia, which is similar to th...
Double-edged sword of pharmaceutical field, CSOs
CSOs(contract sales organizations), a double-edged sword of the pharmaceutical field, have been tested.
According to the pharmaceutical industry, CSOs have been highlighted as reconstruction of products are being act...
AstraZeneca Korea gives notice of staff reduction through ERPAstraZeneca Korea finally seems to push forward with staff reduction.
The AstraZeneca’s headquarters recently announced budget cut guidelines to each global branch, deciding t...
|
Boryung Pharm concludes supply agreement of KRW 85.4 billion worth finished drugs with SandozOn the 20th, Boryung Pharm officially announced the exclusive license and product supply agreement of KRW 85.4 billion to 6 East Asian countries with Sandoz AG, a subsidiary of ...
|
